Pharmacodynamic Effects of Pioglitazone on High Molecular Weight Adiponectin Concentrations and Insulin Response After Oral Sugar in Equids.
Authors: Legere Rebecca M, Taylor Debra R, Davis Jennifer L, Bello Kaitlyn, Parker Caroline, Judd Robert L, Wooldridge Anne A
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: Pioglitazone and Insulin Sensitivity in Horses and Ponies Chronic insulin dysregulation remains notoriously difficult to manage pharmacologically in equids, prompting researchers to investigate pioglitazone—a thiazolidinedione that enhances insulin sensitivity in humans—as a potential therapeutic option for equine metabolic syndrome. This prospective pilot study administered pioglitazone at 2 mg/kg orally once daily for 28 days to fifteen equids (eight ponies and seven horses), measuring morphometric parameters, hepatic enzyme activity, adipokine concentrations, and glucose-insulin responses via oral sugar tests at baseline and throughout treatment. The most clinically significant findings included substantially reduced insulin responses at 90 and 120 minutes post-sugar challenge and a decreased area under the curve in both the pony and insulin-dysregulated subgroups, alongside significantly elevated high-molecular-weight adiponectin concentrations across all treatment groups—changes indicative of improved insulin sensitivity. Notably, blood glucose responses remained unchanged and hepatic enzyme elevations were mild, suggesting pioglitazone was well-tolerated over the treatment period. For practitioners managing equine metabolic syndrome and insulin dysregulation, these results suggest pioglitazone warrants further investigation as an adjunctive therapy to dietary management, though larger clinical trials are needed before routine recommendation can be made.
Read the full abstract on PubMed
Practical Takeaways
- •Pioglitazone shows promise as a pharmacological option for managing insulin dysregulation in horses and ponies, with positive effects on insulin sensitivity markers within 28 days
- •The improvement in HMW adiponectin and reduced insulin response suggests potential benefit for equine metabolic syndrome management, but requires larger clinical trials before routine clinical application
- •Treatment was well-tolerated with only mild hepatic enzyme changes, suggesting reasonable safety profile for short-term use in equids
Key Findings
- •Pioglitazone (2 mg/kg daily for 28 days) significantly decreased insulin response to oral sugar at 90 and 120 minute timepoints in ponies and insulin dysregulated groups
- •High-molecular-weight adiponectin concentrations significantly increased in all treatment groups after pioglitazone administration
- •No significant differences were found in leptin concentrations or blood glucose response to oral sugar testing
- •Mild changes were noted in hepatic enzymes with no significant safety concerns during the 28-day treatment period